vTv Therapeutics (VTVT) News Today → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free VTVT Stock Alerts $25.50 +0.52 (+2.08%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITfinance.yahoo.com - March 19 at 2:34 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Updatefinanznachrichten.de - March 13 at 3:57 PMvTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Updateglobenewswire.com - March 13 at 8:00 AMvTv Therapeutics starts phase 3 trial for diabetes druginvesting.com - March 6 at 4:28 PMThe Top 3 Healthcare Stocks to Buy on Weakness in 2024investorplace.com - March 4 at 3:49 PMvTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetesglobenewswire.com - March 4 at 8:00 AMvTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - March 1 at 8:00 AMvTv Therapeutics' stock doubles after raising $51 million from health care investors including JDRFbizjournals.com - February 29 at 7:40 AMWhy Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today?msn.com - February 28 at 6:07 PMvTv Therapeutics Inc. (VTVT)finance.yahoo.com - February 28 at 6:07 PMNasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrelsmarkets.businessinsider.com - February 28 at 1:07 PMVTv Therapeutics Shares Surge on $51 Million Private Placementmarketwatch.com - February 28 at 1:07 PMmarketbeat.com - February 28 at 11:35 AMmarketbeat.com - February 28 at 11:35 AMmarketbeat.com - February 28 at 11:26 AMvTv Therapeutics Inc. Cl Awsj.com - February 28 at 8:06 AMvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fundfinance.yahoo.com - February 28 at 8:06 AMvTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fundglobenewswire.com - February 28 at 8:00 AMCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCEprnewswire.com - February 22 at 4:00 PMvTv Therapeutics Inc (VTVT)uk.investing.com - January 31 at 8:11 AMvTv Therapeutics Inc - Ordinary Shares - Class Amoney.usnews.com - November 27 at 7:11 PMvTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock splitbizjournals.com - November 21 at 5:53 PMmarketbeat.com - November 21 at 6:06 AMvTv Therapeutics loses $6.7M in Q3, could lose spot on NASDAQ indexbizjournals.com - November 15 at 1:32 PMvTv Therapeutics Stock (NASDAQ:VTVT) Earnings Dates and Earning Callsbenzinga.com - November 11 at 8:11 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - November 10 at 8:42 AMvTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 8:12 PMvTv Therapeutics to Participate at the Stifel 2023 Healthcare Conferencefinance.yahoo.com - November 8 at 8:53 AMvTv Therapeutics appoints Dr. Thomas Strack as chief medical officerbizjournals.com - November 3 at 6:43 PMvTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officerfinance.yahoo.com - November 2 at 9:31 AMvTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Millionfinance.yahoo.com - November 1 at 8:58 AMOne vTv Therapeutics Insider Raised Their Stake In The Previous Yearfinance.yahoo.com - October 19 at 11:54 AMCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19finance.yahoo.com - September 27 at 10:38 AMCantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancerfinance.yahoo.com - September 26 at 11:35 AMCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMAfinance.yahoo.com - September 18 at 10:26 AMIs vTv Therapeutics Inc (VTVT) Modestly Undervalued?finance.yahoo.com - August 24 at 6:06 PMvTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaqfinance.yahoo.com - August 16 at 4:23 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - August 12 at 8:18 AMvTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - August 11 at 5:16 PMCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancerfinance.yahoo.com - August 10 at 11:34 AMNearly half of U.S. adults want weight-loss drugs – KFF pollmsn.com - August 6 at 10:58 PMVTVT - vTv Therapeutics Inc.finance.yahoo.com - July 12 at 12:55 PMvTv Therapeutics Inc - (VTVT) Price Target Decreased by 33.33% to 2.04msn.com - July 6 at 10:29 PMvTv Therapeutics Partner Licenses Exclusive Rights to Intellectual Property for Azeliragonmarketwatch.com - June 16 at 12:16 PMvTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as atmcnet.com - June 16 at 12:16 PMvTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Declinefinance.yahoo.com - June 16 at 12:16 PMCANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTONfinance.yahoo.com - June 15 at 10:25 AMAs it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1bizjournals.com - June 6 at 4:47 PMvTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticalsfinance.yahoo.com - May 24 at 2:17 PMvTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Updatefinanznachrichten.de - May 12 at 8:33 AM Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. VTVT Media Mentions By Week VTVT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTVT News Sentiment▼0.000.37▲Average Medical News Sentiment VTVT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTVT Articles This Week▼01▲VTVT Articles Average Week Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SLS News IFRX News RLYB News YS News ANEB News RVPH News LPTX News AFMD News TPST News LFVN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTVT) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
